

## DAFTAR REFERENSI

- Anderson, T. J., Mancini, G. B. J., Genest, J., Grégoire, J., Lonn, E. M., & Hegele, R. A. (2015). The new dyslipidemia guidelines: What is the debates Canadian Journal of Cardiology, 31(5), 605–612. <https://doi.org/10.1016/j.cjca.2014.11.007>
- Ando, H., Sugimoto, K. I., Yanagihara, H., Tsuruoka, S., Saito, T., Takamura, T., Kaneko, S., & Fujimura, A. (2008). Effects of atorvastatin and pravastatin on glucose tolerance, adipokine levels and inflammatory markers in hypercholesterolaemic patients. Clinical and Experimental Pharmacology and Physiology, 35(9), 1012–1017. <https://doi.org/10.1111/j.1440-1681.2008.04945.x>
- Anneke, R., & Sulistiyarningsih. (2018). Review: Terapi Herbal sebagai Alternatif Pengobatan Dislipidemia. Farmaka, 16, 213–221.
- Arsana, P. M., Rosandi, R., Manaf, A., Budhiarta, A., & Permana, H. (2019). Pedoman Pengelolaan Dislipidemi di Indonesia 2019. In Pb. Perkeni.
- B. Duma , M. Melia, M. E. (2020). Uji Aktivitas AntiHiperkolesterolemia Ekstrak Metannol Buah Belimbing Wuluh (Avverhoa bilimbi Linn) Pada Tikus Putih (Rattus norvegicus) Galur Wistar. 3(April).
- Barrios, V., Escobar, C., & Zamorano, J. L. (2013). Searching the place of pitavastatin in the current treatment of patients with dyslipidemia. Expert Review of Cardiovascular Therapy, 11(12), 1597–1612. <https://doi.org/10.1586/14779072.2013.844546>
- Björnsson, E. S. (2017). Hepatotoxicity of statins and other lipid-lowering agents. Liver International, 37(2), 173–178. <https://doi.org/10.1111/liv.13308>
- Carter, A. A., Gomes, T., Camacho, X., Juurlink, D. N., Shah, B. R., & Mamdani, M. M. (2013a). Risk of incident diabetes among patients treated with statins: Population based study. BMJ (Online), 346(7911), 1–11. <https://doi.org/10.1136/bmj.f2610>

- Carter, A. A., Gomes, T., Camacho, X., Juurlink, N., Shah, B. R., & Mamdani, M. M. (2013b). PENELITIAN Risiko kejadian diabetes di antara pasien yang diobati dengan statin : studi berbasis populasi. 2610, 1–11.
- Casula, M., Mozzanica, F., Scotti, L., Tragni, E., Pirillo, A., Corrao, G., & Catapano, A. L. (2017). Statin use and risk of new-onset diabetes: A meta-analysis of observational studies. *Nutrition, Metabolism and Cardiovascular Diseases*, 27(5), 396–406. <https://doi.org/10.1016/j.numecd.2017.03.001>
- Cederberg, H., Stančáková, A., Yaluri, N., Modi, S., Kuusisto, J., & Laakso, M. (2015). Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort. *Diabetologia*, 58(5), 1109–1117. <https://doi.org/10.1007/s00125-015-3528-5>
- Chapman, M. J., Orsoni, A., Robillard, P., Hounslow, N., Sponseller, C. A., & Giral, P. (2014). Effect of high-dose pitavastatin on glucose homeostasis in patients at elevated risk of new-onset diabetes: Insights from the CAPITAIN and PREVAIL-US studies. *Current Medical Research and Opinion*, 30(5), 775–784. <https://doi.org/10.1185/03007995.2013.874989>
- Chrysant, S. G. (2017). New onset diabetes mellitus induced by statins: current evidence. *Postgraduate Medicine*, 129(4), 430–435. <https://doi.org/10.1080/00325481.2017.1292107>
- Chrysant, S. G. (2017). New onset diabetes mellitus induced by statins: current evidence. *Postgraduate Medicine*, 129(4), 430–435. <https://doi.org/10.1080/00325481.2017.1292107>
- Coleman, C. I., Reinhart, K., Kluger, J., & White, C. M. (2008). The effect of statins on the development of new-onset type 2 diabetes: A meta-analysis of randomized controlled trials. *Current Medical Research and Opinion*, 24(5), 1359–1362. <https://doi.org/10.1185/030079908X292029>
- Crandall, J. P., Mather, K., Rajpathak, S. N., Goldberg, R. B., Watson, K., Foo, S., Ratner, R., Barrett-Connor, E., & Temprosa, M. (2017). Statin use and risk of

developing diabetes: Results from the diabetes prevention program. *BMJ Open Diabetes Research and Care*, 5(1). <https://doi.org/10.1136/bmjdr-2017-000438>

Davies, J. T., Delfino, S. F., Feinberg, C. E., Johnson, M. F., Nappi, V. L., Olinger, J. T., Schwab, A. P., & Swanson, H. I. (2016). Current and emerging uses of statins in clinical therapeutics: A review. *Lipid Insights*, 9(1), 13–29. <https://doi.org/10.4137/LPI.S37450>

Farida, Y., & Claudia Putri. (2016). Efek Penggunaan Simvastatin Terhadap Kenaikan Gula Darah Puasa Pasien Diabetes Melitus Tipe 2. *Journal of Pharmaceutical Science and Clinical Research*, 01(01), 58–65. <https://doi.org/10.20961/jpscr.v1i1.696>

Galicia-Garcia, U., Jebari, S., Larrea-Sebal, A., Uribe, K. B., Siddiqi, H., Ostolaza, H., Benito-Vicente, A., & Martín, C. (2020). Statin treatment-induced development of type 2 diabetes: From clinical evidence to mechanistic insights. *International Journal of Molecular Sciences*, 21(13), 1–25. <https://doi.org/10.3390/ijms21134725>

Genest, J., McPherson, R., Frohlich, J., Anderson, T., Campbell, N., Carpentier, A., Couture, P., Dufour, R., Fodor, G., Francis, G. A., Grover, S., Gupta, M., Hegele, R. A., Lau, D. C., Leiter, L., Lewis, G. F., Lonn, E., Mancini, G. B. J., Ng, D., ... Ur, E. (2009). 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. *Canadian Journal of Cardiology*, 25(10), 567–579. [https://doi.org/10.1016/S0828-282X\(09\)70715-9](https://doi.org/10.1016/S0828-282X(09)70715-9)

Gupta, M., Sharma, R., & Kumar, A. (2019). Comparative potential of Simvastatin, Rosuvastatin and Fluvastatin against bacterial infection: an in silico and in vitro study. *Oriental Pharmacy and Experimental Medicine*, 19(3), 259–275. <https://doi.org/10.1007/s13596-019-00359-z>

Hardiyanti, S., Harmayetty, H., & Widyawati, I. Y. (2019). Kadar Glukosa Darah

Mencit (Mus Musculus) Diabetes Mellitus Paska Pemberian Model Latihan Isometrik. *Critical Medical and Surgical Nursing Journal*, 1(1). <https://doi.org/10.20473/cmsnj.v1i1.11971>

Hori, E. (2019). Departemen Farmasi Klinik , Sekolah Pascasarjana Ilmu Farmasi , Universitas Kota Nagoya ; 3-1.

Hori, E., Kikuchi, C., Imaeda, K., Okayama, N., Suzuki, T., & Matsunagaa, T. (2019). Effect of statins on glycemic status and plasma adiponectin concentrations in patients with type 2 diabetes mellitus and hypercholesterolemia. *Yakugaku Zasshi*, 139(5), 807–815. <https://doi.org/10.1248/yakushi.18-00218>

Karahalil, B., Hare, E., Koç, G., Uslu, İ., Şentürk, K., & Özkan, Y. (2017). Hepatotoksisitas terkait dengan statin. *2994(13)*, 254–260.

Kihara, S. (2013). [Dyslipidemia]. *Nihon Rinsho. Japanese Journal of Clinical Medicine*, 71(2), 275–279. <https://doi.org/10.7326/aitc201712050>

Kim, J., Lee, H. S., & Lee, K. Y. (2018). Effect of statins on fasting glucose in non-diabetic individuals: Nationwide population-based health examination in Korea 11 Medical and Health Sciences 1117 Public Health and Health Services. *Cardiovascular Diabetology*, 17(1), 1–11. <https://doi.org/10.1186/s12933-018-0799-4>

Ko, M. J., Jo, A. J., Kim, Y. J., Kang, S. H., Cho, S., Jo, S. H., Park, C. Y., Yun, S. C., Lee, W. J., & Park, D. W. (2019). Time- and Dose-Dependent Association of Statin Use With Risk of Clinically Relevant New-Onset Diabetes Mellitus in Primary Prevention: A Nationwide Observational Cohort Study. *Journal of the American Heart Association*, 8(8). <https://doi.org/10.1161/JAHA.118.011320>

Liu, A., Wu, Q., Guo, J., Ares, I., Rodríguez, J. L., Martínez-Larrañaga, M. R., Yuan, Z., Anadón, A., Wang, X., & Martínez, M. A. (2019). Statins: Adverse reactions, oxidative stress and metabolic interactions. *Pharmacology and Therapeutics*, 195, 54–84. <https://doi.org/10.1016/j.pharmthera.2018.10.004>

- Machali, I. (2015). Statistik Itu Mudah, Menggunakan SPSS Sebagai Alat Bantu Statistik (Issue 1).
- Moutzouri, E., Liberopoulos, E., Mikhailidis, D. P., Kostapanos, M. S., Kei, A. A., Milionis, H., & Elisaf, M. (2011). Perbandingan efek simvastatin vs . rosuvastatin vs . simvastatin / ezetimibe pada parameter resistensi insulin. 1(November), 1141–1148.
- Novita, E., Ismah, Z., & Elyantari, G. (2018). Pengaruh Atorvastatin 40 Mg Dalam Menurunkan Kadar Kolesterol Pada Penderita Hiperkolesterolemia. *Jurnal Biotek Medisiana Indonesia*, 7(4), 51–60.
- Ruscica, M., MacChi, C., Morlotti, B., Sirtori, C. R., & Magni, P. (2014). Statin therapy and related risk of new-onset type 2 diabetes mellitus. *European Journal of Internal Medicine*, 25(5), 401–406. <https://doi.org/10.1016/j.ejim.2014.03.003>
- Sasaki, J., Ikeda, Y., & Kuribayashi, T. (2008). Perbandingan 52-Minggu , Acak , Label Terbuka , Paralel-Grup dari Tolerabilitas dan Efek Pitavastatin dan Atorvastatin pada Kadar Kolesterol Lipoprotein Densitas Tinggi dan Metabolisme Glukosa pada Pasien Jepang dengan Peningkatan Kadar Kolesterol Lipopro. 30(6), 1089–1101.
- Sri, W. (2015). DISLIPIDEMIA MENYEBABKAN STRESS OKSIDATIF DITANDAI OLEH MENINGKATNYA MALONDIALDEHID. <http://library1.nida.ac.th/termpaper6/sd/2554/19755.pdf>
- Steen, D. L., & Bhatt, D. L. (2014). Statin potency associated with incident diabetes in a real-world evaluation. *Evidence-Based Medicine*, 19(2), 68. <https://doi.org/10.1136/eb-2013-101445>
- Sudrajad, G. B., Kusuma, A. S., & Kusumaratna, R. K. (2020). Paradigma baru penggunaan statin: efek kardioprotektif atau penyebab onset baru diabetes melitus? *Jurnal Biomedika Dan Kesehatan*, 3(2), 101–108. <https://doi.org/10.18051/jbiomedkes.2020.v3.101-108>

- Sugiyama, S., Fukushima, H., Kugiyama, K., Maruyoshi, H., Kojima, S., Funahashi, T., Sakamoto, T., Horibata, Y., Watanabe, K., Koga, H., Sugamura, K., Otsuka, F., Shimomura, I., & Ogawa, H. (2007). Pravastatin improved glucose metabolism associated with increasing plasma adiponectin in patients with impaired glucose tolerance and coronary artery disease. *Atherosclerosis*, 194(2). <https://doi.org/10.1016/j.atherosclerosis.2006.08.023>
- Sultan, S., D'Souza, A., Zabetakis, I., Lordan, R., Tsoupras, A., Kavanagh, E. P., & Hynes, N. (2019). Statins: Rationale, mode of action, and side effects. *The Impact of Nutrition and Statins on Cardiovascular Diseases*, 171–200. <https://doi.org/10.1016/B978-0-12-813792-5.00006-9>
- Thongtang, N., Ai, M., Otokozawa, S., Himbergen, T. V., Asztalos, B. F., Nakajima, K., Stein, E., Jones, P. H., & Schaefer, E. J. (2011). Effects of maximal atorvastatin and rosuvastatin treatment on markers of glucose homeostasis and inflammation. *American Journal of Cardiology*, 107(3), 387–392. <https://doi.org/10.1016/j.amjcard.2010.09.031>
- Ward, N. C., Watts, G. F., & Eckel, R. H. (2019). Statin Toxicity: Mechanistic Insights and Clinical Implications. *Circulation Research*, 124(2), 328–350. <https://doi.org/10.1161/CIRCRESAHA.118.312782>